Tokyo Tape
Sign in
← Jmdc

Quarterly report · Q2

4483.TEDINET S100S9E5
Period2023-04-01 → 2023-09-30
Filed2023-11-13
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
MetricValuePeriodScopeSource row
Revenue¥13.7bn2023-04-01 → 2023-09-30Cons.Revenue IFRS
Revenue¥7.0bn2023-07-01 → 2023-09-30dCons.Revenue IFRS
Revenue¥27.8bn2022-04-01 → 2023-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥12.1bn2022-04-01 → 2022-09-30Cons.Revenue IFRS
Revenue¥6.3bn2022-07-01 → 2022-09-30dCons.Revenue IFRS
Operating income¥3.6bn2023-04-01 → 2023-09-30Cons.Operating profit loss IFRS
Operating income¥1.1bn2023-07-01 → 2023-09-30dCons.Operating profit loss IFRS
Operating income¥2.2bn2022-04-01 → 2022-09-30Cons.Operating profit loss IFRS
Operating income¥1.1bn2022-07-01 → 2022-09-30dCons.Operating profit loss IFRS
Profit before tax¥3.6bn2023-04-01 → 2023-09-30Cons.Profit loss before tax IFRS
Profit before tax¥1.1bn2023-07-01 → 2023-09-30dCons.Profit loss before tax IFRS
Profit before tax¥5.9bn2022-04-01 → 2023-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥2.2bn2022-04-01 → 2022-09-30Cons.Profit loss before tax IFRS
Profit before tax¥1.1bn2022-07-01 → 2022-09-30dCons.Profit loss before tax IFRS
Net income (owners)¥2.7bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥621m2023-07-01 → 2023-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥4.3bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥1.4bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥678m2022-07-01 → 2022-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income¥2.7bn2023-04-01 → 2023-09-30Cons.Profit loss IFRS
Net income¥623m2023-07-01 → 2023-09-30dCons.Profit loss IFRS
Net income¥1.4bn2022-04-01 → 2022-09-30Cons.Profit loss IFRS
Net income¥677m2022-07-01 → 2022-09-30dCons.Profit loss IFRS
Total assets¥100.0bnat 2023-09-30Cons.Assets IFRS
Total assets¥98.6bnat 2023-03-31Cons.Assets IFRS
Total assets¥112.1bnat 2022-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥31.3bnat 2023-09-30Cons.Liabilities IFRS
Total liabilities¥34.0bnat 2023-03-31Cons.Liabilities IFRS
Net assets / equity¥68.7bnat 2023-09-30Cons.Equity IFRS
Net assets / equity¥64.5bnat 2023-03-31Cons.Equity IFRS
Net assets / equity¥61.6bnat 2022-09-30Cons.Equity IFRS
Net assets / equity¥31.2bnat 2022-03-31dCons.Equity IFRS
Equity (owners)¥68.6bnat 2023-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥64.5bnat 2023-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥61.6bnat 2022-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥21.5bnat 2023-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥22.8bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥41.5bnat 2022-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥13.2bnat 2022-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥2.0bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥4.1bn2022-04-01 → 2023-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥1.7bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥3.6bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥22.8bn2022-04-01 → 2023-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥21.5bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow¥341m2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥28.3bn2022-04-01 → 2023-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow¥48.1bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥42.22023-04-01 → 2023-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥9.832023-07-01 → 2023-09-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥71.172022-04-01 → 2023-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥25.292022-04-01 → 2022-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥11.762022-07-01 → 2022-09-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥40.532023-04-01 → 2023-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥9.462023-07-01 → 2023-09-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥67.692022-04-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥23.862022-04-01 → 2022-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥11.142022-07-01 → 2022-09-30dCons.Diluted earnings loss per share IFRS
Equity ratio68.6%at 2023-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio65.5%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio55.0%at 2022-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 71
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥89m
Reconciling Itemsreconcilingrevenue2023-07-01 → 2023-09-30−¥13m
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥89m
Reconciling Itemsreconcilingrevenue intersegment2023-07-01 → 2023-09-30−¥13m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥338m
Reconciling Itemsreconcilingsegment profit2023-07-01 → 2023-09-30−¥187m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue2023-04-01 → 2023-09-30¥1.3bn
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue2023-07-01 → 2023-09-30¥292m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue external2023-04-01 → 2023-09-30¥1.2bn
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue external2023-07-01 → 2023-09-30¥292m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥50m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentsegment profit2023-04-01 → 2023-09-30¥133m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentsegment profit2023-07-01 → 2023-09-30¥45m
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue2023-04-01 → 2023-09-30¥9.8bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue2023-07-01 → 2023-09-30¥5.3bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue external2023-04-01 → 2023-09-30¥9.8bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue external2023-07-01 → 2023-09-30¥5.3bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥38m
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue intersegment2023-07-01 → 2023-09-30¥13m
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentsegment profit2023-04-01 → 2023-09-30¥2.5bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentsegment profit2023-07-01 → 2023-09-30¥1.2bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentrevenue2023-04-01 → 2023-09-30¥2.7bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentrevenue2023-07-01 → 2023-09-30¥1.4bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentrevenue external2023-04-01 → 2023-09-30¥2.7bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentrevenue external2023-07-01 → 2023-09-30¥1.4bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentsegment profit2023-04-01 → 2023-09-30¥1.0bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentsegment profit2023-07-01 → 2023-09-30¥566m
—segment totalrevenue2023-04-01 → 2023-09-30¥13.8bn
—segment totalrevenue2023-07-01 → 2023-09-30¥7.1bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥13.7bn
—segment totalrevenue external2023-07-01 → 2023-09-30¥7.0bn
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥89m
—segment totalrevenue intersegment2023-07-01 → 2023-09-30¥13m
—segment totalsegment profit2023-04-01 → 2023-09-30¥3.6bn
—segment totalsegment profit2023-07-01 → 2023-09-30¥1.8bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥126m
Reconciling Itemsreconcilingrevenue2022-07-01 → 2022-09-30−¥67m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥126m
Reconciling Itemsreconcilingrevenue intersegment2022-07-01 → 2022-09-30−¥67m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥189m
Reconciling Itemsreconcilingsegment profit2022-07-01 → 2022-09-30−¥99m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue2022-04-01 → 2022-09-30¥1.8bn
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue2022-07-01 → 2022-09-30¥933m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue external2022-04-01 → 2022-09-30¥1.8bn
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue external2022-07-01 → 2022-09-30¥890m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥84m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue intersegment2022-07-01 → 2022-09-30¥42m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentsegment profit2022-04-01 → 2022-09-30¥192m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentsegment profit2022-07-01 → 2022-09-30¥144m
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue2022-04-01 → 2022-09-30¥7.9bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue2022-07-01 → 2022-09-30¥4.2bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue external2022-04-01 → 2022-09-30¥7.9bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue external2022-07-01 → 2022-09-30¥4.1bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥42m
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue intersegment2022-07-01 → 2022-09-30¥24m
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentsegment profit2022-04-01 → 2022-09-30¥2.0bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentsegment profit2022-07-01 → 2022-09-30¥903m
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentrevenue2022-04-01 → 2022-09-30¥2.4bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentrevenue2022-07-01 → 2022-09-30¥1.3bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentrevenue external2022-04-01 → 2022-09-30¥2.4bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentrevenue external2022-07-01 → 2022-09-30¥1.3bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentsegment profit2022-04-01 → 2022-09-30¥924m
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentsegment profit2022-07-01 → 2022-09-30¥485m
—segment totalrevenue2022-04-01 → 2022-09-30¥12.2bn
—segment totalrevenue2022-07-01 → 2022-09-30¥6.4bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥12.1bn
—segment totalrevenue external2022-07-01 → 2022-09-30¥6.3bn
—segment totalrevenue intersegment2022-04-01 → 2022-09-30¥126m
—segment totalrevenue intersegment2022-07-01 → 2022-09-30¥67m
—segment totalsegment profit2022-04-01 → 2022-09-30¥3.1bn
—segment totalsegment profit2022-07-01 → 2022-09-30¥1.5bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 887
ItemContextValueUnit
Inventories ca IFRSPrior1YearInstant275000000JPY
Inventories ca IFRSCurrentQuarterInstant194000000JPY
Other current assets ca IFRSPrior1YearInstant601000000JPY
Other current assets ca IFRSCurrentQuarterInstant621000000JPY
Current assets IFRSPrior1YearInstant38240000000JPY
Current assets IFRSCurrentQuarterInstant36641000000JPY
Property plant and equipment IFRSPrior1YearInstant10772000000JPY
Property plant and equipment IFRSCurrentQuarterInstant11230000000JPY
Goodwill IFRSPrior1YearInstant39824000000JPY
Goodwill IFRSCurrentQuarterInstant42101000000JPY
Intangible assets IFRSPrior1YearInstant5922000000JPY
Intangible assets IFRSCurrentQuarterInstant5396000000JPY
Other financial assets nca IFRSPrior1YearInstant1597000000JPY
Other financial assets nca IFRSCurrentQuarterInstant2424000000JPY
Deferred tax assets IFRSPrior1YearInstant2057000000JPY
Deferred tax assets IFRSCurrentQuarterInstant1901000000JPY
Other non current assets nca IFRSPrior1YearInstant152000000JPY
Other non current assets nca IFRSCurrentQuarterInstant305000000JPY
Non current assets IFRSPrior1YearInstant60326000000JPY
Non current assets IFRSCurrentQuarterInstant63359000000JPY
Assets IFRSPrior1YearInstant98567000000JPY
Assets IFRSCurrentQuarterInstant100000000000JPY
Borrowings cl IFRSPrior1YearInstant994000000JPY
Borrowings cl IFRSCurrentQuarterInstant3031000000JPY
Trade and other payables cl IFRSPrior1YearInstant5790000000JPY
Trade and other payables cl IFRSCurrentQuarterInstant5506000000JPY
Lease liabilities cl IFRSPrior1YearInstant846000000JPY
Lease liabilities cl IFRSCurrentQuarterInstant855000000JPY
Income taxes payable cl IFRSPrior1YearInstant1201000000JPY
Income taxes payable cl IFRSCurrentQuarterInstant1018000000JPY
Contract liabilities cl IFRSPrior1YearInstant2066000000JPY
Contract liabilities cl IFRSCurrentQuarterInstant2152000000JPY
Other current liabilities cl IFRSPrior1YearInstant1317000000JPY
Other current liabilities cl IFRSCurrentQuarterInstant1183000000JPY
Total current liabilities IFRSPrior1YearInstant12216000000JPY
Total current liabilities IFRSCurrentQuarterInstant13748000000JPY
Borrowings ncl IFRSPrior1YearInstant11935000000JPY
Borrowings ncl IFRSCurrentQuarterInstant8045000000JPY
Lease liabilities ncl IFRSPrior1YearInstant6623000000JPY
Lease liabilities ncl IFRSCurrentQuarterInstant6817000000JPY
Retirement benefit liability ncl IFRSPrior1YearInstant322000000JPY
Retirement benefit liability ncl IFRSCurrentQuarterInstant150000000JPY
Provisions ncl IFRSPrior1YearInstant692000000JPY
Provisions ncl IFRSCurrentQuarterInstant429000000JPY
Deferred tax liabilities IFRSPrior1YearInstant730000000JPY
Deferred tax liabilities IFRSCurrentQuarterInstant716000000JPY
Contract liabilities ncl IFRSPrior1YearInstant1520000000JPY
Contract liabilities ncl IFRSCurrentQuarterInstant1379000000JPY
Non current labilities IFRSPrior1YearInstant21825000000JPY
Non current labilities IFRSCurrentQuarterInstant17539000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-07-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2022-07-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2023-07-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass